Vaxcyte Inc (PCVX)

NASD · Healthcare · Biotechnology · USA

Vaxcyte Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Intrinsic value, DCF valuation, financial health and value investing analysis for the Vaxcyte Inc stock.

Our verdict on PCVX

Not valued: We cannot value this company yet.

ETFs with the most weight in PCVX

Fidelity Disruptive Medicine ETF (FMED): 1.8% of the fund
Janus Henderson Transformational Growth ETF (JXX): 1.8% of the fund
T. Rowe Price Health Care ETF (TMED): 1.2% of the fund

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 598 Biotechnology stocks

Cheaper than PCVX in Biotechnology

Arbutus Biopharma Corp (ABUS): undervalued, 79% margin of safety
Lakefront Biotherapeutics NV ADR (LKFT): undervalued, 77% margin of safety
CorMedix Inc (CRMD): undervalued, 74% margin of safety
MeiraGTx Holdings plc (MGTX): undervalued, 73% margin of safety
Bicycle Therapeutics Plc ADR (BCYC): undervalued, 71% margin of safety
Innoviva Inc (INVA): undervalued, 71% margin of safety

134 more in this industry show a wider margin of safety.

Is PCVX undervalued or overvalued?

We do not publish a verdict on PCVX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of PCVX?

We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.